secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0000950170-25-033064
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome settles Sunosi patent litigation with Hikma; generic entry deferred to 2040
--------------------------------------------------------------------------------

- Settlement with Hikma resolves patent litigation over Sunosi (solriamfetol) generic.
- License for Hikma's generic Sunosi begins Sept 1, 2040 (with pediatric exclusivity) or March 1, 2040 (without).
- Agreement subject to FTC/DOJ review; other patent litigation against other parties remains pending.
- Axsome retains exclusive Sunosi rights until at least 2040, protecting key product revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025033064/0000950170-25-033064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025033064/axsm-20250305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-033064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer